NasdaqGS:BBIOBiotechs
BridgeBio Pharma Sees Pivotal Shift As Late Stage Success Meets Attruby Sales
BridgeBio Pharma (NasdaqGS:BBIO) released positive top line Phase 3 data for Encaleret, BBP-418 and Infigratinib.
The company reported strong commercial momentum for its product Attruby, supporting a move toward cash generation.
Management framed this combination of clinical and commercial news as a pivotal inflection in the business model.
BridgeBio Pharma comes into this update with a current share price of $66.445 and a very large 3 year return, alongside a 90.4% return over the past...